# US 9,752,194 B2 · Methods and compositions useful for diagnosing inflammatory bowel disease-associated neoplasia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,752,194 B2
- Document ID: US9752194B2
- Status: Granted
- Kind: B2
- Application number: 14/398,535
- Filed: 2013-05-03
- Published: 2015-05-14
- Granted: 2017-09-05
- Earliest claimed: 2012-05-03
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Alexandru V. Olaru; Stephen J. Meltzer
- Web page: https://patentgrep.com/patent/US9752194B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/10: in screening processes
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of microRNAs to diagnose and monitor various diseases such as cancer. In particular embodiments, microRNA expression levels can serve as diagnostic biomarkers in inflammatory bowel disease-associated neoplasia (IBDN). More specifically, in certain embodiments, the present invention can be used to differentiate or distinguish IBDN from sporadic colorectal cancer (S-CRC), IBD-Dysplasia, IBD and/or normal.

## Claims

### Claim 1

A method comprising measuring the levels of a panel of microRNAs comprising miR-21, miR-192, miR-200b, miR-224, miR-7, miR-95, miR-124, miR-138, miR-214, miR-452 and miR-1305 from a biological sample obtained from a patient, wherein the patient has inflammatory bowel disease (IBD) or IBD-dysplasia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the measuring step is accomplished using quantitative real-time polymerase chain reaction (qRT-PCR) or a microarray.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sample is blood, plasma or serum.

### Claim 4 (depends on 3)

The method of claim 3, wherein the sample is blood.

### Claim 5 (depends on 3)

The method of claim 3, wherein the sample is plasma.

### Claim 6 (depends on 3)

The method of claim 3, wherein the sample is serum.